Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Last trade$0.1901
Day change+$0.0058 (+3.15%)
Day range$0.178 – $0.192
Volume325,611
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.31M
Price / earnings
—
Price / book
0.34×
Price / sales
3.32×
EV / sales
-3.47×
EV / EBITDA
0.12×
Profitability
Earnings per share
-$1.46
Return on assets
-189.18%
Return on equity
-276.16%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.07×
Quick ratio
3.07×
Cash ratio
1.52×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$62.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VTGN, quarterly periods
Line item
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Q2 FY2025 Sep 30, 2024
Revenue
$1.48M
$465K
$303K
$258K
$244K
—
$234K
$183K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.48M
$465K
$303K
$258K
$244K
—
$234K
$183K
Selling, general and administrative
$3.92M
$4.12M
$5.63M
$4.4M
$4.37M
—
$4.05M
$4.2M
Research and development
$10.91M
$13.06M
$14.22M
$15.92M
$11.68M
—
$11.31M
$10.22M
Total operating expenses
$14.82M
$17.18M
$19.85M
$20.31M
$16.05M
—
$15.35M
$14.41M
Operating income
-$13.35M
-$16.72M
-$19.55M
-$20.05M
-$15.8M
—
-$15.12M
-$14.23M
Interest expense
$0
$2.44M
$0
$0
$0
—
$0
$0
Income before taxes
-$13.03M
-$16.27M
-$18.9M
-$19.42M
-$15.1M
—
-$14.09M
-$12.95M
Income taxes
$0
$7K
$0
$0
$0
—
$0
$7K
Net income
-$13.03M
-$16.27M
-$18.9M
-$19.42M
-$15.1M
—
-$14.09M
-$12.96M
Net income attributable to common shareholders
-$13.03M
-$16.27M
-$18.9M
-$19.4M
-$15.1M
—
-$14.09M
-$12.94M
EBITDA
-$13.3M
-$16.67M
-$19.49M
-$20M
-$15.76M
$40K
-$15.08M
-$14.19M
Basic earnings per share
-$0.30
-$0.38
-$0.45
-$0.54
-$0.47
—
-$0.46
-$0.42
Diluted earnings per share
-$0.30
-$0.38
-$0.45
-$0.54
-$0.47
—
-$0.46
-$0.42
Recent news
Company coverage with links to the original publishers.
Kuehn Law is investigating whether officers and directors of Vistagen Therapeutics breached fiduciary duties by misrepresenting or failing to disclose risks in their Social Anxiety Disorder clinical trials. The firm alleges insiders downplayed known issues with public speaking challenge endpoints, including elevated placebo responses and site variability, while promoting the PALISADE-3 trial as likely to succeed. The law firm is seeking shareholders who purchased stock prior to April 1, 2024.
A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) alleging that defendants made materially false and misleading statements regarding the company's drug fasedienol and its Phase 3 PALISADE-3 clinical trial. Investors who purchased VTGN stock between April 1, 2024 and December 16, 2025 may be eligible for compensation. The deadline to serve as lead plaintiff is March 16, 2026.
A class action lawsuit has been filed against Vistagen Therapeutics for alleged securities fraud, claiming the company made materially false and misleading statements about its fasedienol drug candidate and the PALISADE-3 clinical trial while concealing adverse data. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the case, with a lead plaintiff deadline of March 16, 2026.
The Schall Law Firm is seeking investors who purchased Vistagen Therapeutics securities between April 1, 2024 and December 16, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its fasedienol drug candidate's Phase 3 success potential in the PALISADE-2 trial and downplayed clinical failure risks, resulting in investor losses.
Rosen Law Firm is notifying investors in Vistagen Therapeutics who purchased stock between April 1, 2024 and December 16, 2025 of a March 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Vistagen made false and misleading statements about its drug fasedienol and the PALISADE-3 clinical trial, providing overly positive assertions while concealing material adverse facts about the Phase 3 trial.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.